Dong Mei, Yu Ting, Zhang Zhenzhen, Zhang Jing, Wang Rujian, Tse Gary, Liu Tong, Zhong Lin
Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, China.
Medical College, Qingdao University, Qingdao 266003, China.
J Cardiovasc Dev Dis. 2022 Jun 28;9(7):203. doi: 10.3390/jcdd9070203.
Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive research based on different types of ICIs, these studies have not indicated whether cardiotoxicity is specific to a type of cancer. Therefore, we conducted a systematic review to analyze a variety of ICIs-related cardiotoxicity, focusing on different types of cancer. We found that the incidence of ICIs-related cardiac adverse events (CAEs) and common cardiotoxic manifestations vary with cancer type. This inspired us to explore the underlying mechanisms to formulate targeted clinical strategies for maintaining the cardiovascular health of cancer patients.
免疫检查点抑制剂（ICIs）是迅速发展的免疫疗法癌症药物，已延长了患者的生存期。然而，与ICIs相关的心脏毒性已被认为是一种罕见但致命的后果。尽管基于不同类型的ICIs已经进行了广泛的研究，但这些研究并未表明心脏毒性是否特定于某一类型的癌症。因此，我们进行了一项系统综述，以分析各种与ICIs相关的心脏毒性，重点关注不同类型的癌症。我们发现，与ICIs相关的心脏不良事件（CAEs）的发生率和常见心脏毒性表现因癌症类型而异。这促使我们探索潜在机制，以制定针对性的临床策略，维护癌症患者的心血管健康。
